Table 5 Summary of published studies reporting the expression of ALDH1 in carcinoma
Number of patients | Patient population (Publication year) | Tissue and methods | Expression compared to normal tissue | Association with high histologic grade | Association with high TNM staging | Expression in metastasis compared to primary | Prognostic factor |
|---|---|---|---|---|---|---|---|
Breast cancer | |||||||
106 | Triple negative mammary carcinoma (2011) [31] | FFPE, IHC | N/A | ↑ for epithelial cells - for stromal cells | N/A | N/A | ↓for epithelial cells |
606 | Invasive mammary carcinoma, DCIS (2012) [24] | TMA, IHC | N/A | ↑ | - | N/A | N/A |
140 | 2012-Triple negative mammary carcinoma [25] | TMA, IHC | N/A | - | - | N/A | ↑ for stromal cells |
Gastrointestinal cancer | |||||||
190 | Gastric carcinoma (2012) [32] | FFPE, IHC | N/A | ↑ | ↑ | ↑ | - |
96 | Colorectal carcinoma (2012) [29] | FFPE, IHC | ↑ | N/A | ↓ | ↓ | - |
1420 | Colorectal carcinoma (2010) [33] | TMA, IHC | ↓ | + | N/A | N/A | - |
186 | Colorectal carcinoma (2012) [34] | TMA, IHC | N/A | N/A | N/A | N/A | ↓ (for cells that were positive for beta-catenin in the nucleus) |
Gynecological cancer | |||||||
442 | Ovarian carcinoma (2009) [28] | TMA, IHC | N/A | - | ↓ | N/A | ↑ |
84 | Ovarian carcinoma (2012) [35] | TMA, IHC | N/A | - | - | N/A | ↓ |
28 | Serous ovarian carcinoma (2010) [36] | TMA, IHC, RT-PCR, Western | ↓ | N/A | N/A | N/A | N/A |
98 | Endometrioid ovarian carcinoma (2010) [37] | IHC | N/A | - | ↑ | N/A | ↓ |
Hepatobiliary and pancreatic cancer | |||||||
49 | Hepatocellular carcinoma (2012) [38] | FFPE, IHC | N/A | ↓ | - | N/A | ↑ |
100 | Gallbladder adenocarcinoma (2010) [26] | FFPE, IHC | ↑ | ↑ | N/A | N/A | ↓ |
97 | Pancreatic adenocarcinoma (2011) [39] | IHC, RT-PCR, Western | N/A | - | - | N/A | ↑ |
78 | Pancreatic adenocarcinoma (2012) [40] | TMA, IHC | N/A | N/A | N/A | N/A | - |